INTERogating Cancer for Etiology, Prevention and Therapy Navigation

RecruitingOBSERVATIONAL
Enrollment

350

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

September 30, 2033

Study Completion Date

September 30, 2033

Conditions
CancerCancer Gene MutationPAN Gene MutationHematopoietic and Lymphoid System NeoplasmMalignant Solid Neoplasm
Interventions
GENETIC

Pan-genomic Testing

Participants will be scheduled to review the study specifics, review consent and gather medical information. Once consented, samples will be collected. When the samples are received by Exact Sciences, DNA and RNA will be extracted, and sequencing will be performed. Following pan-genomic testing, participants will receive the full report with results from their care team and results will also be added to the patient's portal. If a germline finding is identified (positive pathogenic variant) the participant will also be referred for a genetic counselor visit. All results from the germline hereditary test will be reviewed by a certified genetic counselor in addition to a review of their pedigree. To help with review of any genetic research findings, the study team may request to obtain genomic data from previous genetic testing (clinical or research based).

Trial Locations (3)

32224

RECRUITING

Mayo Clinic in Florida, Jacksonville

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

85259

RECRUITING

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06008392 - INTERogating Cancer for Etiology, Prevention and Therapy Navigation | Biotech Hunter | Biotech Hunter